We are live on ! Find out more
GCM

Graham Capital Management Portfolio holdings

AUM $4.14B
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+8.47%
1 Year Est. Return
+17.82%
3 Year Est. Return
+41.13%
5 Year Est. Return
+43.39%
10 Year Est. Return
+274.46%
AUM
$6.62B
AUM Growth
+$902M
Cap. Flow
+$1.08B
Cap. Flow %
16.3%
Top 10 Hldgs %
50.26%
Holding
1,697
New
464
Increased
345
Reduced
451
Closed
433

Sector Composition

Rank Sector Weight
1 Technology 5.74%
2 Financials 5.16%
3 Industrials 4.35%
4 Consumer Discretionary 3.72%
5 Healthcare 3.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
B
1201
Barrick Mining
B
$73.2B
$86.9K ﹤0.01%
+4,175
New +$81.6K
PGEN icon
1202
Precigen
PGEN
$2.59B
$84.4K ﹤0.01%
59,425
+48,116
+425% +$68.4K
INSG icon
1203
Inseego
INSG
$90.5M
$83.1K ﹤0.01%
10,079
-10,997
-52% -$85.9K
FULC icon
1204
Fulcrum Therapeutics
FULC
$297M
$82.9K ﹤0.01%
12,052
-154,191
-93% -$825K
DUOL icon
1205
PUT
Duolingo
DUOL
$6.12B
$82K ﹤0.01%
+200
New +$87.8K
COGT icon
1206
Cogent Biosciences
COGT
$7.24B
$81.3K ﹤0.01%
11,328
-62,665
-85% -$347K
ERAS icon
1207
Erasca
ERAS
$6.39B
$81.1K ﹤0.01%
63,824
+21,815
+52% +$29.2K
AVD icon
1208
American Vanguard Corp
AVD
$68.9M
$80.3K ﹤0.01%
20,489
-31,446
-61% -$131K
KW
1209
DELISTED
Kennedy-Wilson Holdings
KW
$80K ﹤0.01%
11,758
-33,716
-74% -$225K
LESL icon
1210
Leslie's
LESL
$11M
$76.3K ﹤0.01%
9,088
-59,612
-87% -$785K
ASPN icon
1211
Aspen Aerogels
ASPN
$518M
$74.7K ﹤0.01%
12,623
-154,336
-92% -$888K
RCEL icon
1212
Avita Medical
RCEL
$240M
$73.9K ﹤0.01%
+13,976
New +$102K
HLLY icon
1213
Holley
HLLY
$384M
$73.3K ﹤0.01%
36,666
-6,911
-16% -$14.7K
RXT icon
1214
Rackspace Technology
RXT
$1.24B
$72.9K ﹤0.01%
56,968
+5,332
+10% +$6.95K
WOW
1215
DELISTED
WideOpenWest
WOW
$72.4K ﹤0.01%
17,828
-4,444
-20% -$19.1K
VSTM icon
1216
Verastem
VSTM
$610M
$67.9K ﹤0.01%
+16,361
New +$102K
KLTR icon
1217
Kaltura
KLTR
$267M
$67.5K ﹤0.01%
+33,576
New +$69.6K
REAL icon
1218
The RealReal
REAL
$1.5B
$62.7K ﹤0.01%
13,092
-299,468
-96% -$1.65M
CRDF icon
1219
Cardiff Oncology
CRDF
$77.2M
$59K ﹤0.01%
+18,718
New +$57.1K
GOSS icon
1220
Gossamer Bio
GOSS
$87M
$57.7K ﹤0.01%
46,894
+17,917
+62% +$19.5K
MREO
1221
Mereo BioPharma
MREO
$47.3M
$57.4K ﹤0.01%
21,176
-28,242
-57% -$68.2K
SRG
1222
Seritage Growth Properties
SRG
$136M
$55K ﹤0.01%
17,850
-21,235
-54% -$61.2K
CMPS
1223
Compass Pathways
CMPS
$1.83B
$53.8K ﹤0.01%
+19,213
New +$72.3K
DEFT
1224
Defi Technologies
DEFT
$183M
$53.3K ﹤0.01%
+18,187
New +$60.9K
SRTA
1225
Strata Critical Medical Inc
SRTA
$512M
$51.6K ﹤0.01%
12,805
-25,652
-67% -$83.5K

Similar funds

Graham Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Graham Capital Management held 1,697 positions worth $6.62B, up 16% from $5.72B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Graham Capital Management deployed $1.08B of net new capital in Q2 2025, opening 464 new positions and adding to 345 existing holdings. Its largest new stake was Vanguard Morningstar Value ETF: 110,000 shares worth $19.4M.

By sector, the portfolio is most concentrated in Technology at 5.7% of assets, up from 5.5% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Citigroup, an estimated $16.9M trimmed.

  • Graham Capital Management's largest Q2 2025 buy was Vanguard Morningstar Value ETF: 110,000 shares worth $19.4M.
  • Graham Capital Management added most to iShares Bitcoin Trust in Q2 2025, an estimated $19.3M increase.
  • Graham Capital Management's biggest Q2 2025 reduction was Citigroup, cutting an estimated $16.9M.
  • Graham Capital Management fully exited Pacer Developed Markets International Cash Cows 100 ETF in Q2 2025, selling an estimated $15.6M.
  • Graham Capital Management's ten largest holdings make up 50% of its $6.62B portfolio in Q2 2025.
  • Graham Capital Management opened 464 new positions and closed 433 in Q2 2025.
  • Graham Capital Management's portfolio value rose 16% quarter-over-quarter to $6.62B.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.